Interleukin-12, interleukin-23, and psoriasis: ABT-874 in clinical trials

Journal of the American Academy of Dermatology

Volumn 58, Issue 6, 2008, Pages 1083-

  Wu, Jashin J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABT 874; INTERLEUKIN 12; INTERLEUKIN 23;

CLINICAL TRIAL; DISEASE SEVERITY; DRUG MECHANISM; HUMAN; INJECTION SITE REACTION; LETTER; PRIORITY JOURNAL; PSORIASIS VULGARIS; RHINOPHARYNGITIS; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; HUMANS; INTERLEUKIN-12; INTERLEUKIN-23; PSORIASIS;

EID: 43249104766     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2008.01.024     Document Type: Letter

References (3)

1. Torti D.C., and Feldman S.R. Interleukin-12, interleukin-23, and psoriasis: current prospects. J Am Acad Dermatol 57 (2007) 1059-1068
2. Kimball A.B., Gordon K.B., and Valdes J.M. Safety and efficacy of the fully human IL-12/-23 monoclonal antibody, ABT-874, in the treatment of moderate to severe psoriasis: results from a phase II trial. J Invest Dermatol 127 (2007) S54
3. Kimball A.B., Gordon K.B., Langley R.G., Menter A., Chartash E.K., and Valdes J. ABT-874 Psoriasis Study Investigators. Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial. Arch Dermatol 144 (2008) 200-207